The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in patients with high-risk ...
The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
The subcutaneous administration (under the skin) of bortezomib, a standard treatment in patients with multiple myeloma (cancer of the bone marrow), is as effective as standard intravenous delivery ...
The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License ...
Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas. This article ...
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...
The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner Merck (MSD) in the U.S.
argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart's 1000 mg dose, administered through a subcutaneous ...
The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback